<DOC>
	<DOCNO>NCT01064089</DOCNO>
	<brief_summary>This study phase I dose escalation , multi-center , open-label study HSP990 administer orally weekly adult Japanese Korea patient advance solid malignancy .</brief_summary>
	<brief_title>Dose Escalation HSP990 Japan/Korea</brief_title>
	<detailed_description />
	<criteria>1 . Patients advance solid tumor ( advanced cancer ) 2 . Patient 's disease must evaluable use RECIST criterion 3 . Patients must 18 old Korea 20 old Japan 4 . Patients must relatively healthy measure performance status 5 . Patients must acceptable laboratory value measure blood test 6 . Patients must able swallow capsule 7 . Patients must understand study give write permission enter study 1 . Patients brain tumor 2 . Patients prior medicine similar study drug HDAC inhibitor medicine 3 . Patients must classify `` poor intermediate CYP2C9 metabolizer '' measure use sample blood 4 . Patients must recover previous anticancer therapy 5 . Patients must finish take previous anticancer therapy enter study 6 . Patients must severe disease time study entry ( example : severe diarrhea , disease liver kidney , cancer , etc . ) 7 . Patients must relatively good heart function Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>HSP990</keyword>
	<keyword>HSP90</keyword>
	<keyword>Japan/Korea</keyword>
	<keyword>Phase I</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>dose escalation</keyword>
	<keyword>maximum tolerate dose</keyword>
	<keyword>MTD</keyword>
	<keyword>Japanese paatients</keyword>
	<keyword>Korean patient</keyword>
</DOC>